Gilenya

Mavenclad found comparable to Gilenya in highly active MS

Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups ā€” but…

High-efficacy DMTs Boost Mid-term Prognosis for Relapsing MS: Study

People with relapsing multiple sclerosis (MS) treated with Tysabri (natalizumab) or Gilenya (fingolimod) are less likely to have disease activity than those on low-efficacy MS medications, according to a small study conducted in Japan. Results also showed that patients receiving the high-efficacy therapies had less brain shrinkage,…

Expert Voices: Understanding pediatric multiple sclerosis research and care

In this installment of our ā€œExpert Voicesā€ series, Multiple Sclerosis News Today asked Tanuja Chitnis, MD, to answer some of your questions about pediatric multiple sclerosis (MS). Chitnis is a board-certified neurologist specializing in multiple sclerosis-related neuroimmunological disorders. Chitnis’s interest in children with MS led her to create…

Higher COVID-19 Risk Tied to 2 MS Therapies, Even With Vaccination

Fully vaccinated multiple sclerosis (MS) patients who are treated with Ocrevus (ocrelizumab) or Gilenya (fingolimod) have a significantly higher risk of COVID-19 infection than those given other immunosuppressive therapies, according to a study in Italy. Called breakthrough infections, these post-vaccination cases of SARS-CoV-2 ā€” the virus that causes…

Marriage, Education, DMT Affect Patients’ Treatment Adherence

Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…

3D Showing of Mayzent Binding to Receptor Could Advance Treatments

For the first time, researchers have brought to light the precise three-dimensional structure ofĀ Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1). These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing…

#ACTRIMS2022 ā€“ Algorithm Predicts Relapse Risk Using EHR Data

Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model predicts a patient’s future one-year MS relapse risk with clinically actionable accuracy, comparable to other clinical…

MS Hiker Laces Up Her Boots for Appalachian Trail

Reservations at a base lodge have been made, and a starting date is circled on her calendar. MS hiker April Hester is ready to start up the Appalachian Trail in the eastern U.S. It’s always an uphill hike for April, even when the trail is flat. She was diagnosed with…

COVID Booster May Benefit Patients on Anti-CD20 Therapy

Multiple sclerosis (MS) patients with weak immune responses to COVID-19 vaccines are more likely to respond successfully to the booster shot if they are receiving an anti-CD20 therapy compared with those on Gilenya (fingolimod), according to a small study in Norway. These early findings suggest that booster shots…

Ocrevus, Gilenya May Limit Efficacy of COVID-19 Vaccines: UK Study

COVID-19 infection rates after widespread vaccination were significantly higher among multiple sclerosis (MS) patients on Ocrevus (ocrelizumab) or Gilenya (fingolimod) than in the general population, but not among MS patients given other immunosuppressive disease-modifying therapies (DMTs), a data study in England reports. While information on patientsā€™ vaccination…

Santa Is Not Cominā€™ to Town!

This is the fifth year I’m writing a Christmastime missive about how my MS journey as Santa is going since the disease mortally attacked my immune system. The trouble was that it took doctors ages to work out my diagnosis. Being Santa Claus, no MRI machine…